Slingshot Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Slingshot Biosciences, Inc. holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 23 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 8 trademarks are registered and 14 are pending. Notable registered marks include SB, VIACOMP, TRUCYTES, FLOWCYTES, and SLINGSHOT. The owner is based in Emeryville, CA.
1250 4th St., Suite 330
Emeryville, CA 94608
Showing of trademarks Trademarks
Trademark Classifications
Slingshot Biosciences, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Slingshot Biosciences, Inc. have?
Slingshot Biosciences, Inc. has 23 U.S. trademarks filed with the USPTO. Of these, 8 registered, 14 pending, 1 abandoned.
What trademark classes does Slingshot Biosciences, Inc. file in?
Slingshot Biosciences, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Slingshot Biosciences, Inc.'s most well-known trademarks?
Slingshot Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as SB, VIACOMP, TRUCYTES, FLOWCYTES, and SLINGSHOT. These are among 8 currently registered trademarks in the portfolio.
What is Slingshot Biosciences, Inc.'s trademark registration success rate?
Slingshot Biosciences, Inc. has a 89% trademark registration rate, with 8 out of 9 resolved applications resulting in successful registration. Currently, 14 applications are pending review.